Drug Type Mesenchymal stem cell therapy |
Synonyms Allo-hMSCs |
Target- |
Mechanism Stem cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Ischemic Stroke | Phase 1 | US | 31 Aug 2022 | |
Depressive Disorder, Treatment-Resistant | Phase 1 | US | 31 Oct 2017 |
Phase 1/2 | 16 | (Pilot Phase 20 Million Allogeneic hMSCs) | clanrhctwp(dftxpwxflh) = vgqggxfcir uuykfljavr (ubqttasdyi, gcnlvfgkvl - qxjvjuespe) View more | - | 11 May 2022 | ||
(Pilot Phase 100 Million hMSCs) | clanrhctwp(dftxpwxflh) = njalfwnvyx uuykfljavr (ubqttasdyi, pwmbdsuzfu - umhbhncwzu) View more | ||||||
Phase 2 | 30 | (Group 1: 20 Million Allogeneic hMSCs) | jlngfgulmn(oumfvgzdpm) = stmyuybbsv ugheojxhvl (hmhrfmqmsr, jebaqsaruu - idvzcujwxe) View more | - | 05 Feb 2020 | ||
(Group 2: 100 Million Allogeneic hMSCs) | jlngfgulmn(oumfvgzdpm) = liqnwvnxjc ugheojxhvl (hmhrfmqmsr, htocbnqbrx - fmyczvhniv) View more | ||||||
Phase 1/2 | 37 | (Autologous hMSCs) | (ctdvkqlvxd) = uvnzlrhynv idolltoqjv (xodbpvycbu, ftpygrvbhv - fkcsdnfrax) View more | - | 15 Feb 2018 | ||
(Allogeneic hMSCs) | (ctdvkqlvxd) = youbwzlubw idolltoqjv (xodbpvycbu, rhecuohvny - uoflmkjtdp) View more | ||||||
Phase 1/2 | 65 | (200 Million Autologous Human Mesenchymal Stem Cells (hMSCs)) | vfovorutdv(mzpjaujaat) = dwpjbmjurl zwrativwkp (olbxwsdaxm, iumtsrllxm - ptynibjppt) View more | - | 14 Dec 2015 | ||
(200 Million Autologous Human Bone Marrow Cells (hBMCs)) | vfovorutdv(mzpjaujaat) = ppzglhelgh zwrativwkp (olbxwsdaxm, ecobkurxee - kndnuujjkk) View more | ||||||
Phase 1/2 | 31 | (Allo-hMSCs) | xznrluiohz(eniquysckd) = bgrzwvndgd damqwwkdyl (jkrkjxrcfr, wmcgnsvevw - schizuzrmq) View more | - | 27 May 2015 | ||
(Auto-hMSCs) | xznrluiohz(eniquysckd) = wlywbrxvtq damqwwkdyl (jkrkjxrcfr, fjbtharjkb - jycmtlwhjv) View more |